期刊文献+

依西美坦治疗绝经后妇女晚期乳腺癌的临床疗效观察 被引量:3

Clinical Study of Postmenopausal Women Patients with Late Breast Cancer Treated with Exemestane
下载PDF
导出
摘要 目的 研究依西美坦治疗绝经后妇女晚期乳腺癌的近期疗效及不良反应。方法 采用随机双盲对照方法将 48例绝经后晚期乳腺癌患者分为治疗组 (依西美坦组 ,2 3例 )和对照组 (来曲唑组 ,2 5例 ) ,治疗 8周。治疗前及治疗第 4周、第 8周分别检测血中雌二醇 (E2 )水平 ,同时观察疗效和不良反应。结果 治疗组与对照组治疗有效率分别为 3 9.1% (9 2 3 )与 2 8.0 % (7 2 5 )。ER阳性者的疗效较阴性者好 ;软组织和骨转移者的疗效明显较肝、肺及内脏转移者好 ;2组治疗后对E2的平均有效抑制率分别为3 2 .5 %与 5 5 .1% ;治疗组的胃部不适、恶心、呕吐、颜面潮红等不良反应发生率显著低于对照组。结论 依西美坦对E2的抑制作用和对绝经后晚期乳腺癌的疗效肯定 。 Objective This study was designed to investigate the effect and side effect when exemestane was delivered to postmenopausal women patients with late breast cancer.Methods The selective patients were divided into Group A(23 patients) and Group B(25 patients),who took exemestane and letrozol with randomly double blind control test for 8 weeks.E2 levels were examined during pretreat and treat in the forth and the eighth week,meanwhile clinical effect and side effect were observed.Results The effective rate of Group A and Group B was 39.1% and 28.0%,respectiuely.With regard to effect,postive ER was significantly prior to negative ER and soft tissue and bone metastasis was prior to liver,lung and internal organ metastasis as well.Post treatment mean effective restrained rates for E2 level were 32.5% and 55.1%,respectiuely.Group A had less side effect than Group B,such as uncomfortable stomach,nausea,vomit,red face.Conclusion It is certain that exemestane may restrain E2 level and may be effective for postmenopausal women late breast cancer.Side effect is less.
机构地区 江西省肿瘤医院
出处 《实用癌症杂志》 2002年第5期542-544,共3页 The Practical Journal of Cancer
关键词 绝经 疗效观察 乳腺肿瘤 药物治疗 依西美坦 不良反应 内分泌治疗 Breast tumor Medincine therapy Exemestane Letrozol E2
  • 相关文献

参考文献2

二级参考文献10

  • 1Marty M,Gershanovich M,Campos D,et al.Letrozole, a new potent, selective aromatase inhibitor superrior to aminoglutethimide in postmenopausal women with advanced breast cancer previously treated with antiestrogens〔J〕[].Proceedings of the American Society of Clinical Oncology.1997
  • 2Iveson TJ,Smith IE,Ahern J,et al.Phase Ⅰ study of the oral nonste-rioidal aromatase inhitor CGS 20267 in postmenopausal patients with advanced breast cancer〔J〕[].Cancer.1993
  • 3Lamb HM,Adkins JC.Letrozole—a reviews of its use in postmenopausal women with advanced breast cancer〔J〕[].Drugs.1998
  • 4Dixon JM,Love CDB,Tucker S,et al.Letrozole as primary medical therapy for locally advanced and large operable breast cancer〔J〕[].Proceedings of the American Society of Clinical Oncology.1998
  • 5Rubens RD.Advanced Breast Cancer: Reassessing Hormonmal Therapy〔M〕[]..1996
  • 6Bhatnagar AS,Hausler A,Schieweck K.Inhibition of aromatase in vitro and in vivo by aromatase inhibitors〔J〕[].Journal of Enzyme Inhibition.1990
  • 7Ingle JN,Johnson PA,Suman VJ,et al.A randomized phase Ⅱtrial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma〔J〕[].Cancer.1997
  • 8Bajetta E,Zilembo N,Guillevin L,et al.Endocrine trial comparing 0. 5 and 2. 5 mg of letrozole in postmenopausal patients(pts)with advanced breast cancer (ABC)〔J〕[].Proceedings of the American Society of Clinical Oncology.1998
  • 9Zilembo N,Guillevin L,Dowset M,et al.Endocrine trial comparing 0. 5 and 2. 5 mg of letrozole in postmenopausal patients(PTS)with advanced breast cacncer (ABC)〔J〕[].Proceedings of the American Society of Clinical Oncology.1998
  • 10Dombernowsky P,Smith I,Falkson G,et al.For the letrozole AR/BCZ International Study Group.Double blind randomized phase Ⅱb/Ⅲtrial of two doses of letrozole and megestrol acetate as second-line treatment for patients with breast cancer(abstr)〔J〕[].Annals of Oncology.1996

共引文献23

同被引文献60

  • 1Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 2008, Part2: Table 8.5.c.
  • 2Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol, 2008, 26(30): 4883-4890.
  • 3Coombes RC, Kilbum LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet, 2007, 17(369): 559-570.
  • 4Semiglazov V, Kletsel A, Semiglazov V, et al. exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0-M0). J Clin Oncol, 2005, 23(16 Suppl):11S.
  • 5Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol, 2003, 14(9): 1391-1398.
  • 6Chow LW. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol, 2008, 111(1-2): 13-17.
  • 7Mayordomo l, Llombart A, Martin M, et al. Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal paitnets (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Journal of Clinical Oncology, 2006, 24(18 Suppl): 37s.
  • 8张象麟,张克坚,赖琪,等.药物临床信息参考2007版.四川科学技术出版社(成都),2007,942-944.
  • 9Gibson LJ, Dawson CL, Lawrence DJ, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. The Cochrane Collaboration, 2007, Issue 1:1-2.
  • 10吴在德 吴肇汉.外科学:第6版[M].北京:人民卫生出版社,2004.330.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部